<DOC>
	<DOCNO>NCT02846142</DOCNO>
	<brief_summary>This trial consist three part : first two part enroll healthy female volunteer single ascend dose ( SAD ) multiple ascend dose ( MAD ) treatment group . The SAD treatment group comprise least 3 cohort subject randomize single dose either PTI-428 placebo follow 7 day post dose . A total 24 subject anticipate participate part study . Following conclusion respective SAD level dose group sufficient review study data approval SRC , second set healthy adult female subject participate assign MAD treatment group . The MAD treatment group comprise 3 cohort subject randomize either PTI-428 placebo follow total 14 day . The SRC convene completion cohort evaluate safety , PK relevant data . The SRC determine whether proceed next plan dose level , reduce dose , stop study . The next cohort may commence write SRC approval . A total 24 subject anticipate participate part study . Following completion SAD MAD , 40 female healthy volunteer participate two treatment period DDI study component : Treatment period A consist daily oral contraceptive ( OC ) 28-days ( 21-day hormonal active + 7 day ) . Treatment period B randomize subject PTI-428 placebo combination daily OC 28 day ( 21-day hormonal active PTI-428 placebo + 7 day ) . Following completion subject ' second treatment period , follow 7-days last dose .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , PK , ECG Effects , Drug-drug Interaction ( DDI ) Hormonal Contraceptives PTI-428 Healthy Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Adult female age 18 55 year old , inclusive , time informed consent . For DDI Oral Contraceptive Cohort , woman child bear potential intact ovarian function medical history history regular menstrual . cycle . Body mass index ( BMI ) â‰¥18 &lt; 30 kg/m2 . Subject must nonsmoker nontobacco user minimum 30 day prior screen duration study . Subject understand full nature purpose study , include possible risk side effect , willing able comply compulsory study procedure provide informed consent/permission prior study procedure perform . History current evidence clinically significant cardiac , endocrinologic , hematologic , hepatobiliary , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator . Abnormal liver function define : Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) bilirubin &gt; 1.5 x upper limit normal range . Abnormal renal function screen define : Creatinine clearance &lt; 80mL/min use CockroftGault equation . No clinically significant screening result would exclude subject study ( e.g. , medical history , physical examination , ECGs , vital sign , pulse oximetry , laboratory profile ) deem investigator . Participation another clinical trial treatment investigational agent within 30 day 5 halflives , whichever longer , prior Study Day 1 . History cancer within past five year ( exclude nonmelanoma skin cancer ) . History alcohol drug abuse dependence within 12 month screen determined Investigator . Positive urine screen prohibit drug ( cocaine , cannabinoids , nicotine [ urine cotinine detection mechanism nicotine ] , opiates , barbiturate , amphetamine , benzodiazepine ) positive alcohol Breathalyzer . Positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) . Clinically significant infection within 3 month screen determined Investigator . Known suspect hypersensitivity idiosyncratic reaction study medication component thereof . Has donate blood within 3 month screen plan donate blood within 3 month study completion . Pregnant nursing woman . Any condition , opinion Investigator , would make subject unsuitable enrollment could interfere subject 's participation completion study . Females childbearing potential , unless willing use highly effective method contraception participation clinical study 30 day termination study . Use prohibit medication within 14 day prior dose study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>